Sign in
Taking people in United StatesPhase 3

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Ann Arbor, Houston, and St Louis, United StatesSee the 3 sitesAlso in 5 other countries, 26 sites
Status
Recruiting
Phase
Phase 3
People taking part
240 people, planned
Started
20 Aug 2018
Expected to end
1 Jan 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Cisplatin
  • Etoposide
  • Mitotane
  • Quality-of-Life Assessment
Record updated
16 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Have a histologically confirmed diagnosis of ACC (Weiss score of >= 3). (LinWeiss-Bisceglia system will be used for oncocytic ACC)
  • Have a high risk of relapse defined as: Stage I-III ACC (according to the European Network for the Study of Adrenal Tumors [ENSAT] classification) within 90 days of surgical resection of primary tumor with curative intent with either microscopically complete resection (R0, defined as no evidence of microscopic residual disease according to surgical reports, histopathology, and perioperative imaging), microscopically positive margins (R1), or undetermined margins (RX, based on surgical or pathological reports without unequivocal evidence of metastasis in the perioperative imaging). Each participating center will determine the pathological stages and resection margins AND Ki67 > 10% (to be determined by an experienced pathologist in each participating center and preferably via quantitative imaging analysis)
  • Have perioperative imaging (computed tomography [CT] with contrast, magnetic resonance imaging [MRI] of the chest/abdomen/pelvis, or fluorodeoxyglucose positron emission tomography [FDG-PET] CT) without unequivocal evidence of disease within 8 weeks before randomization. Patients with indeterminate non-specific nodules (< 1 cm for soft tissue lesions and < 1.5 cm in the short dimension for lymph nodes) will be permitted to participate in this study
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Be able to comply with the protocol procedures
  • Provide written informed consent

Who cannot take part

  • The time between primary surgery and randomization > 90 days
  • They underwent previous or current treatment with mitotane or other antineoplastic drugs for ACC
  • They underwent previous radiotherapy for ACC
  • Gross residual disease after surgery (R2 resection)
  • High suspicion for metastatic disease on perioperative imaging
  • They have undergone repeated surgery for recurrence of disease
  • They have a history of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 2 years
  • They have renal insufficiency (estimated glomerular filtration rate [GFR] < 50 mL/min/1.73 m\^2)
  • They have significant liver insufficiency (serum bilirubin > 2 times the upper normal range)
  • They have significant liver insufficiency (serum alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times the upper normal range)
  • Impaired bone marrow reserve (neutrophils < 1000/mm\^3)
  • Impaired bone marrow reserve (platelets < 100,000/mm\^3)
  • They have known congestive heart failure (ejection fraction < 45%). The extent of cardiac testing will depend on the judgment of the local principal investigator (PI). In general, in patients with a history of cardiac disease, it is recommended to obtain a baseline two-dimensional echocardiogram as standard of care to document ejection fraction. In patients without prior cardiac disease, a baseline electrocardiogram (EKG) is sufficient if there is no evidence of acute ischemic changes or prior evidence of myocardial infarction. If EKG results are abnormal (ischemic changes, significant arrhythmia, or suggestion of prior myocardial infarction), a two-dimensional echocardiogram will be obtained to assess ejection fraction. Cardiac imaging and EKG may not be needed in patients assigned to mitotane who do not have prior cardiac history and have low suspicion for cardiac symptoms to reflect standards of clinical practice. Similarly, utilizing cardiac imaging and EKG within the past 12 months is permitted if there is no suspicion for cardiac issues
  • They have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would, in the judgment of the investigator, pose excess risk associated with study participation or administration of the involved drugs or that, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • Pregnancy or breast feeding
  • They have preexisting grade 2 peripheral neuropathy

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Adrenocortical carcinoma

This trial is currently available in United States.

Also in 5 other countries, 26 sites

  • University Of Michigan Comprehensive Cancer CenterAnn Arbor, United StatesContact: Francis P. WordenTaking people
  • M D Anderson Cancer CenterHouston, United StatesContact: Jeena VargheseTaking people
  • Siteman Cancer Center at Washington UniversitySt Louis, United StatesContact: Jeena VargheseNo longer taking part

About the trial

What the trial wants to find out

This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.

The 2 groups in the trial

  • Arm A (mitotane)Treatment being tested

    Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

    Treatment: Mitotane and Quality-of-Life Assessment

  • Arm B (mitotane, etoposide, cisplatin)Treatment being tested

    Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

    Treatment: Cisplatin, Etoposide, Mitotane, and Quality-of-Life Assessment

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Criteria questions
Built from NCT03583710, who can take part
Record updated
16 July 2026